ERBB2 and neoplasm: This tumor burden model and the calculation of TSC were proven useful for studying antibody–drug conjugates in oncology, including trastuzumab deruxtecan that targets HER2 and monomethyl auristatin E (MMAE) that targets mesothelin, respectively [108,109,110].